ReviewEndocrine2018
Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.
Review in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 108 citations in OpenAlex.
- Integrating Molecular and Imaging Insights: Ryanodine Receptor 2 (RyR2) Expression, CK18 Status, and Conventional MRI Findings in Pituitary Neuroendocrine Tumors.International journal of molecular sciences · 2026Article
- A rare case of an indolent giant GH-secreting pituitary adenoma.JCEM case reports · 2026Article
- Inflammation, oxidative stress and purinergic signaling in pituitary neuroendocrine tumors (PitNETs).Purinergic signalling · 2026Review
- Giant pituitary adenomas: an institutional experience with 289 surgically treated patients.Acta neurochirurgica · 2026Article
- Effectiveness of a Modified Transsellar Approach with Planum Sphenoidale Removal for Pituitary Neuroendocrine Tumors with Anterosuperior Extension.Journal of clinical medicine · 2026Article
- Predicting resection success in giant pituitary adenomas: morphologic determinants and a preoperative multivariate model.Frontiers in endocrinology · 2026Article
- Endoscopic endonasal resection of giant pituitary adenomas - case series from the referral pituitary center.Pituitary · 2025Article
- Impact of Tumor Size on Prolactinoma Characteristics and Treatment Outcomes: A Study of a Tunisian Cohort.Biomedicines · 2025Article
- Treatment-resistant Cushing disease and acromegaly in a young woman: A case of functional pituitary macroadenoma.Radiology case reports · 2025Article
- Article
- Giant and irregular pituitary neuroendocrine tumors surgery: comparison of simultaneous combined endoscopic endonasal and transcranial and purely endoscopic endonasal surgery at a single center.Chinese neurosurgical journal · 2025Article
- Endoscope-assisted transcranial surgery for complex pituitary adenoma: a retrospective case series study with propensity score matching.Neurosurgical review · 2025Article
- Article
- Clinical presentation and surgical outcomes of very large and giant pituitary adenomas: 80 cases in a cohort study of 306 patients with pituitary adenomas.Acta neurochirurgica · 2024Article
- The expression ofFrontiers in endocrinology · 2024Article
- Giant Clinically Non-Functioning Pituitary Adenoma Presenting as New Onset Generalized Tonic‒Clonic Seizures: A Case Report.International medical case reports journal · 2024Article
- Article
- How we do it: the double keyhole micro-endoscopic combined complex pituitary adenoma surgery.Acta neurochirurgica · 2023Article
- Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study.The Journal of clinical endocrinology and metabolism · 2023Article
- Acromegaly complicated with fulminant pituitary apoplexy: clinical characteristic analysis and review of literature.Endocrine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant pituitary adenomas comprise about 6-10% of all pituitary tumors. They are mostly clinically non-functioning adenomas and occur predominantly in males. The presenting symptoms are usually secondary to compression of neighboring structures, but also due to partial or total hypopituitarism. Functioning adenomas give rise to specific symptoms of hormonal hypersecretion. The use of dopamine agonists is considered a first-line treatment in patients with giant macroprolactinomas. Somatostatin analogs can also be used as primary treatment in cases of growth hormone and thyrotropin producing giant adenomas, although remission of the disease is not achieved in the vast majority of these patients. Neurosurgical treatment, either through transsphenoidal or transcranial surgery, continues to be the treatment of choice in the majority of patients with giant pituitary adenomas. The intrinsic complexity of these tumors requires the use of different therapies in a combined or sequential way. A multimodal approach and a therapeutic strategy involving a multidisciplinary team of expert professionals form the basis of the therapeutic success in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.